TRC105

TRC105 is a monoclonal antibody that is being developed for the treatment of various types of cancer. It is designed to target endoglin, a protein that is overexpressed on the surface of cancer cells and is involved in angiogenesis, the process by which new blood vessels form.

Mechanism of Action

TRC105 works by binding to endoglin on the surface of cancer cells. This binding inhibits the function of endoglin, which in turn inhibits angiogenesis. By preventing the formation of new blood vessels, TRC105 can starve the cancer cells of the nutrients they need to grow and proliferate.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of TRC105 in various types of cancer. These trials have shown promising results, with some patients experiencing significant reductions in tumor size and others achieving complete remission.

Side Effects

Like all drugs, TRC105 can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and diarrhea. In rare cases, TRC105 can cause serious side effects such as severe allergic reactions.

Future Directions

Research is ongoing to further evaluate the potential of TRC105 in the treatment of cancer. Future studies will likely focus on identifying the types of cancer that are most responsive to TRC105, as well as determining the optimal dosing regimen and combination therapies.

TRC105 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia